Stock Valuation / GMED
Is Globus Medical, Inc. (GMED) Overvalued? Fair Value & 5-Year Target
Globus Medical, Inc. trades at $76.32 (P/E 19.62). Our reference model estimates a fair value of $141.27 at its recent average P/E of 36.32.
| Current price | $76.32 |
|---|---|
| Current EPS | $3.89 |
| Current P/E | 19.62 |
| Average P/E | 36.32 |
| Fair value (at avg P/E) | $141.27 |
| Upside to fair value | +85.1% |
| Illustrative 5-yr target (25× P/E, 15% growth) | $195.60 |
What drives GMED's valuation
Changing either assumption moves the target: a higher P/E multiple or faster EPS growth raises fair value, a lower multiple or slower growth lowers it. The interactive dashboard lets you edit both and re-run the model instantly.
About Globus Medical, Inc.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstructio
Frequently asked questions
What is GMED's fair value?
At its recent average P/E of 36.32, Globus Medical, Inc. (GMED) has a reference fair value of about $141.27, which is +85.1% versus the current price of $76.32.
Is Globus Medical, Inc. (GMED) overvalued or undervalued?
Based on the average-P/E reference model, Globus Medical, Inc. looks undervalued relative to fair value by roughly +85.1%. This is a model output, not investment advice — change the P/E and growth assumptions in the dashboard for your own view.
What is a 5-year price target for GMED?
Under an illustrative model of 25× P/E and 15% annual EPS growth, the implied 5-year target is $195.60. Adjust both inputs on the interactive page to match your assumptions.
Open the interactive GMED valuation dashboard →
Figures are for informational purposes only and are not investment advice. Data as of 2026-10-14.